Bioinicia introduces its GMP manufacture of electrospun drug delivery products

The UK-China Mini-Symposium on Electrospinning for Drug Delivery took place last April 18th at University College London’s School of Pharmacy. This event welcomed many experts in the electrospinning field, as well as professors and students from pharmaceutical and biomedical sectors.

Dr. Tom Hayes, Product & Technology Specialist of Bioinicia, was there presenting "GMP manufacture of electrospun drug delivery products: A first case study". His introduction was warmly received and he had the opportunity to present Bioinicia´s state-of-the art project with Dermtreat ApS, a Danish-based biopharmaceutical company focused on innovative approaches to the treatment of mucosal diseases.

Bionicia is currently manufacturing, in behalf of Dermtreat ApS, the novel Rivelin® patch which provides uni-directional mucosal drug delivery for the treatment of Oral Lichen Planus, a chronic condition that affects 1-2% of the population.

Recently, Eureka by PatSnap, the newsletter for R&D, IP and innovation experts, has published a post on electrospinning technology in regards to this event. In this publication they show the electrospinning process concisely and how Bioinicia produce clinical grade electrospun biomaterials. The newsletter states that our client DermtreatApS is the most patent-intensive new electrospinning for medical purposes company.

About Bioinicia

Bioinicia S.L. is a privately held materials science and engineering company dedicated to the development, industrial scale-up and manufacturing of nano- and microstructured materials by electro-hydro dynamic processes (i.e. electrospinning and electrospraying) for their clients and providing premium quality equipment for laboratory to industrial-scale processing.

Bioinicia acts as a partner for product development, electrospinning-electrospraying technology and industrial manufacturing.

For additional information, please visit www.bioinicia.com.

About Dermtreat

Dermtreat ApS is a Danish-based, private, biopharmaceutical company focused on innovative approaches to the treatment of mucosal diseases. Dermtreat’s lead product candidate is using its novel Rivelin® patch for the treatment of Oral Lichen Planus, a chronic condition that affect 1-2% of the population. The Rivelin® patch incorporates clobetasol propionate to treat OLP and is planned to commence a clinical Phase 2b study in April 2018.

Shareholders include Sofinova Ventures, Lundbeckfonden Emerge, Novo Seeds and Welfare Tech Invest.

For additional information, please visit www.rivelin.eu.